Patent Code Changes: Dangerous Precedent Or Unique Circumstance? Supreme Court Seeks Government's Views
This article was originally published in The Pink Sheet Daily
Executive Summary
Generic companies contend that the Caraco v. Novo Nordisk case could enable brand firms to game the system and delay generic approvals; Novo says the case may never happen again.